secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001213900-26-002185
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics appoints COO Jeet Mahal as CEO; Ron Martell steps down, Thomas Wiggans named Executive Chair
--------------------------------------------------------------------------------

- Effective Jan 5, 2026, Jeet Mahal becomes CEO and President; he also joins the Board as Class III director.
- Outgoing CEO Ron Martell's departure is without cause; he receives 18 months base salary plus COBRA for up to 18 months.
- Thomas Wiggans, current Board Chair, appointed Executive Chair effective Jan 5, 2026.
- Mahal's annual salary increased to $600,000 with eligibility for performance bonus up to 50% of base salary.
- Company to host investor webinar on Jan 8, 2026 to present updated data from BEACON study and open-label extension in CSU/CIndU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026002185/0001213900-26-002185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026002185/ea0271735-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-002185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer